For two decades, dementia researchers laboured in a quagmire. Promising drug trials collapsed, a reliable diagnostic test remained elusive, and billions of dollars yielded little progress. Pharmaceutical companies began pulling out of the field, even as dementia surged to become Australia's number one killer.
That impasse has now lifted. The World Alzheimer Report 2026, released late last month, notes the field is entering a period of 'remarkable scientific momentum'. Australia's Therapeutic Goods Administration approved the first two drugs to successfully modify Alzheimer's disease last year. Just two months ago, a blood test capable of detecting biomarkers with 92 per cent accuracy up to 20 years before the first symptom was also approved.
The momentum is visible in a global pipeline of 158 drugs being tested across 192 trials, spanning new brain-penetrating agents, mRNA vaccines and repurposed medications.
'It's like an explosion in developments across the board,' said Professor Kaarin Anstey of UNSW, who sits on the World Health Organisation's dementia panel. Associate Professor Emma Devenney, a neurologist, recalled being urged to avoid the field because it was considered so futile. 'This is changing the trajectory, which we haven't been able to do until now,' she said.